Tech Mahindra and NVIDIA Collaborate to Advance Drug Safety Using Agentic AI

Tech Mahindra, in collaboration with NVIDIA, has introduced an advanced pharmacovigilance (PV) solution powered by agentic AI technology. The solution aims to enhance the accuracy, speed, and efficiency of drug safety management processes by automating and optimizing critical pharmacovigilance workflows.

Key Highlights
Launch of Pharmacovigilance Autonomous Solution

• The solution is built using Tech Mahindra’s TENO framework and NVIDIA’s AI technologies, including NVIDIA NeMo, NIM microservices, and AI Blueprints.

• It automates PV workflows such as case intake, data transformation, quality control, and compliance management, reducing manual delays and errors.

Performance Improvements in Pharmacovigilance

• Reduces turnaround time of adverse drug reaction (ADR) case processing by up to 40%.

• Enhances data accuracy by 30% and cuts operational costs by 25%.

• AI-driven agents autonomously handle case classification, prioritization, and email verification, ensuring seamless PV workflow.

Expansion of TENO Framework

• Integrates NVIDIA AI Enterprise software to include AI agents tailored for a variety of industry challenges.

• Combines NVIDIA NeMo for generative AI data collection and Tech Mahindra’s VerifAI solution for data validation and governance.

• Distributed training and model customization ensure continuous AI model evolution for improved decision-making.

Statements from Leaders or Officials
Tech Mahindra and NVIDIA emphasized the partnership’s commitment to advancing patient safety outcomes. Their collaboration brings agentic AI intelligence to the pharmacovigilance sector, addressing critical challenges like manual delays and data overload, which often hinder timely drug safety assessments.This partnership positions Tech Mahindra and NVIDIA at the forefront of transforming pharmacovigilance from reactive to predictive. The AI-powered solution is set to redefine drug safety management by enabling faster, more accurate, and compliant handling of ADR cases, thus ensuring better healthcare outcomes globally.